Study proposes value-based price for Lilly's necitumumab

A necitumumab ( LY3012211) from Eli Lilly and Co. (NYSE:LLY). Necitumumab is under FDA review in combination with gemcitabine and cisplatin as first-line treatment for advanced squamous non-small cell lung cancer (NSCLC); an FDA decision is expected by year end.

The study authors said they determined a cost-effective price for necitumumab using data from the Phase III SQUIRE trial, in which three-week cycles of necitumumab plus chemotherapy increased median overall survival (OS) by 1.6 months (HR=0.84) in patients with metastatic squamous NSCLC. The study estimated necitumumab's incremental cost-effectiveness ratio (ICER) to be $100,000-$200,000 per quality-adjusted life year (QALY) gained. ...